Highlights Clearside Biomedical, Inc.

Equities

CLSD

US1850631045

Real-time Estimate Cboe BZX Other stock markets 01:14:34 2024-05-02 pm EDT			5-day change	1st Jan Change
1.345 ^USD	+5.91%		+7.14%	+15.38%

Apr. 16	Clearside Biomedical, Inc Appoints Anthony S. Gibney to its Board of Directors	CI
Mar. 18	Clearside Biomedical Names Victor Chong Chief Medical Officer	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Clearside Biomedical, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 12	CI
Clearside Biomedical, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 12	CI
Clearside Biomedical, Inc. Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD	Dec. 14	CI
Clearside Biomedical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
BioCryst Pharmaceuticals, Clearside Biomedical Enter Drug Development Collaboration	Nov. 03	MT
Biocryst Pharmaceuticals, Inc. and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside's Proprietary Scs Microinjector	Nov. 03	CI
Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting	23-10-16	CI
Clearside Biomedical, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Clearside Biomedical Highlights Excellent Safety Profile of CLS-AX and Potential for Extended Duration of Effect in Data Presentation At the American Society of Retina Specialists 41st Annual Scientific Meeting	23-07-31	CI
Clearside Biomedical Says Application of Arcatus for Treatment of Uveitic Macular Edema Accepted for Review in Australia	23-07-10	MT
Clearside Biomedical Asia-Pacific Partner Arctic Vision Announces the Acceptance in Australia of Its New Drug Application for Suprachoroidal Use of ArcatusÂ® for the Treatment of Uveitic Macular Edema	23-07-10	CI
Clearside Biomedical, Inc. Opens Enrollment in Odyssey Phase 2B Clinical Trial of Cls-Ax (Axitinib Injectable Suspension) in Wet AMD	23-06-01	CI
Clearside Biomedical, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Clearside Biomedical, Inc. Announces Plans for ODYSSEY Phase 2b Clinical Trial of CLS-AX (Axitinib Injectable Suspension) in Wet AMD	23-04-18	CI
CLEARSIDE BIOMEDICAL, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	23-03-14	AQ
Clearside Biomedical, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-03-09	CI
Clearside Biomedical, Inc. Announces Initiation of Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Expected in Second Quarter of 2023	23-03-09	CI
Clearside Biomedical, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-03-09	CI
Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD	23-02-02	CI
Clearside Biomedical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Clearside Biomedical, Inc.

Equities

CLSD

US1850631045

Highlights

Filters